

1 **Identification of *Acinetobacter baumannii* and detection of  $\beta$  - lactam antibiotic resistance genes**  
2 **in clinical samples by multiplex PCR**

3 Phan-Canh Trinh<sup>a</sup>, Le-Thi-Thanh Thao<sup>a</sup>, Ngo-Thi-Bich Thuy<sup>a</sup>, Nguyen-Thi-Thanh Thanh<sup>a</sup>, Ho-Le-  
4 Truc Linh<sup>a</sup>, Tu-Anh Nguyen<sup>a,\*</sup>

5 <sup>a</sup>Department of Microbiology and Parasitology, Faculty of Pharmacy, University of Medicine and  
6 Pharmacy at Ho Chi Minh City, Ho Chi Minh 700000, Vietnam

7 \* **Corresponding author; Present address:** Department of Microbiology and Parasitology,  
8 Faculty of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh  
9 700000, Vietnam.

10 **Tu-Anh Nguyen** **Tel.:** + 84 9381 303 72; **E-mail address:** [nguyentuanh@ump.edu.vn](mailto:nguyentuanh@ump.edu.vn).

11  
12 **Keywords:** *Acinetobacter baumannii*,  $\beta$ -lactam antibiotic resistance gene, hospital-acquired  
13 infection, multiplex PCR, colony PCR.

14

15

## 16 **Highlights**

- 17 • 100% of isolates of *A. baumannii* contains the *bla*<sub>OXA-51-like</sub> gene and the *AmpC* gene.
- 18 • 34/46 isolates possess the gene *bla*<sub>TEM</sub>, however, do not contain *bla*<sub>CTX-M</sub> and *bla*<sub>SHV</sub> genes.
- 19 • Combined disc test with cefotaxime/clavulanic acid/boronic acid is an excellent method to  
20 analyse ESBL phenotype.

## 21 **Abstract**

22 *Acinetobacter baumannii* is the leading cause of hospital-acquired infection in Vietnam. Of note,  
23 antibiotic resistance genes are significantly popular in clinical isolates of *A. baumannii*. Therefore,  
24 rapid identification of *A. baumannii* and determination of antibiotic resistance genes will help to  
25 make effective clinical decisions related to antibiotic use. This paper proposes a multiplex PCR to  
26 identify *Acinetobacter baumannii* and detect their  $\beta$ -lactam antibiotic resistance genes in clinical  
27 isolates. Multiplex PCR was applied to amplified *recA* gene and region ITS 16S - 23S rDNA for  
28 Rapid detection of *A. baumannii*. The two antibiotic resistance genes - *bla*<sub>OXA-51-like</sub>, *ampC* gene -  
29 were detected by multiplex PCR and three genes coding Extended-spectrum beta-lactamases -  
30 *bla*<sub>CTX-M</sub>, *bla*<sub>TEM</sub>, *bla*<sub>SHV</sub> genes - were subjected to PCR. 49 bacteria strains were subjected to colony  
31 PCR. The result showed that 46 strains were *A. baumannii* and 3 strains belonged to the genus  
32 *Acinetobacter*. The multiplex PCR showed that all of 46 *A. baumannii* containing the *bla*<sub>OXA-51-like</sub>  
33 gene and the *AmpC* gene; 34 strains possess the gene *bla*<sub>TEM</sub> and none of them has *bla*<sub>CTX-M</sub> and  
34 *bla*<sub>SHV</sub> genes. The results of the multiplex PCR are the same as those of the *in vitro* antibiotic  
35 sensitivity testing of *A. baumannii*. However, applying the multiplex PCR directly from the bacteria  
36 colony, we can proceed simultaneously with the bacterial identification and the antibiotic resistance  
37 gene detection.

38 **Keywords:** *Acinetobacter baumannii*,  $\beta$ -lactam antibiotic resistance gene, hospital-acquired  
39 infection, multiplex PCR, colony PCR.

40

## 41 **1. Introduction**

42 Currently, in the world as well as in Vietnam, *Acinetobacter baumannii* is one of the major causes  
43 of hospital – acquired infections [1]. Besides the increase in infection rate, there are *A. baumannii*  
44 strains possessing antibiotic resistance genes which code the enzyme hydrolyzing new generation  
45 antibiotics such as carbapenem. *A. baumannii* is also capable of producing the extended-spectrum  
46 beta-lactamase (ESBL) enzyme and thus can destroy most of the penicillin and broad-spectrum  
47 cephalosporin antibiotics [2]. According to a report by the Centers for Disease Control and  
48 Prevention (CDC) in 2013, there were about 63% of multidrug resistance *A. baumannii* infections  
49 [3]. Based on a review by the Global Antimicrobial Resistance Coordinator (2009), more than 60%  
50 of isolated *A. baumannii* were collected in some hospitals such as Bach Mai Hospital, Cho Ray  
51 Hospital and Central Hospital for Tropical Diseases (in Viet Nam) is multidrug-resistant [4].  
52 For infectious diseases, rapid and accurate identification of pathogenic bacteria plays an important  
53 role in diagnosis and treatment. The traditional microbiological methods such as biochemical tests,  
54 antimicrobial susceptibility techniques, spend a lot of time. Meanwhile, applying the multiplex  
55 PCR, we can proceed simultaneously with the bacterial identification and antibiotic resistance gene  
56 detection. Therefore, research on the specific genes and antibiotic resistance genes in *A. baumannii*  
57 isolated from clinical samples by multiplex PCR was conducted. In this study, rapid detection of *A.*  
58 *baumannii* by multiplex PCR technique was carried out for determining the conservation gene *recA*  
59 that specified for the genus *Acinetobacter* and the region-specific ITS 16S - 23S rDNA of *A.*  
60 *baumannii* [5,6]. The antibiotic resistance genes including the *bla*<sub>OXA-51-like</sub> gene - carbapenem  
61 resistance, *AmpC* gene - cephalosporin resistance [7,8] and three genes coding Extended-spectrum  
62 beta-lactamases (ESBL) - *bla*<sub>CTX-M</sub>, *bla*<sub>TEM</sub>, *bla*<sub>SHV</sub> genes were selected [9–11]. There are four  
63 groups of enzymes in the OXA-type carbapenemase family that are commonly present in *A.*  
64 *baumannii*, OXA-23, OXA-24, OXA-58, OXA-51-like. Recently, scientists have discovered the  
65 *bla*<sub>Oxa-51-like</sub> gene coding for the OXA-51-like enzymes on the chromosome and the natural  
66 antibiotic resistance gene of *A. baumannii*. Particularly, group A β-lactamase is the ESBL, it is able

67 to destroy the third-generation cephalosporins such as ceftazidime, cefepime, cefotaxime and  
68 ceftriaxone, but not carbapenem. ESBLs mainly belong to the TEM and SHV  $\beta$ -lactamase groups,  
69 caused by mutations on one nucleotide of the *bla*<sub>TEM</sub> and *bla*<sub>SHV</sub> genes. In addition, ESBL types  
70 CTX-M, VEB-1, PER-1 are also common, especially ESBL CTX-M encoded by the *bla*<sub>CTX-M</sub> gene.

## 71 **2. Material and Methods**

### 72 *2.1. Bacteria strains*

73 49 isolates of *Acinetobacter* spp., mostly from bronchial-fluid samples, were provided by the  
74 General Hospital in Binh Duong province, Viet Nam. These bacteria were identified by biochemical  
75 tests in the former experiments in this hospital. These isolates were cultured in Tryptic Soy Broth  
76 (TSB - Merck) before being streaked on MacConkey agar (MCA - Merck) to harvest colonies that  
77 were subjected to colony PCR.

### 78 *2.2. Rapid detection of A. baumannii by multiplex PCR technique (RD-PCR)*

79 The multiplex PCR technique (RD-PCR) was applied to determine the conservation gene *recA* (425  
80 bp) that specifies for the genus *Acinetobacter* with the primers P-rA1 - P-rA2 and the region-  
81 specific ITS 16S - 23S rDNA (208 bp) of *A. baumannii* with the primers P-Ab-ITSF - P-Ab-ITSB  
82 (**Table 1**) [5,6]. The RD-PCR reaction with a total reaction volume of a 25  $\mu$ l consists of 2.5  $\mu$ l PCR  
83 buffer (10X), 1.0  $\mu$ l each of dNTPs (10 mM), 4.0  $\mu$ l MgSO<sub>4</sub> (25 mM), 1.0  $\mu$ l each of primers (10  
84  $\mu$ M), 0.1  $\mu$ l *Taq* DNA polymerase (5.0 UI), 1.0  $\mu$ l bacterial suspension (one colony was dispersed in  
85 20  $\mu$ l TSB medium), and distilled water. PCR amplification process was carried out with an Labnet  
86 MultiGene™ OptiMax thermal cycler under the following conditions: initial denaturation (94 °C, 3  
87 min); 30 cycles of denaturation (94 °C, 30 sec), annealing (51 °C, 30 sec), extension (72 °C, 45  
88 sec); final extension (72°C, 5 min). PCR products were analysed by electrophoresis on 1% agarose  
89 gel (Sigma-Aldrich), containing SafeView (ABM), and UV visualization were performed on Gel  
90 Documentation System WGD-30 (DAIHAN Scientific Korean). *Bacillus subtilis* PY79 was used as  
91 a negative control.

92

93 2.3. *Detection of the  $\beta$ -lactamase genes of A. baumannii by multiplex PCR*  
 94 *technique (B-PCR)*

95 The B-PCR with a total reaction volume of a 25  $\mu$ l includes 2.5  $\mu$ l PCR buffer (10X), 1.0  $\mu$ l each of  
 96 dNTPs (10 mM), 4.0  $\mu$ l MgSO<sub>4</sub> (25 mM), 1.0  $\mu$ l each of *bla*<sub>OXA-51-like</sub> primers and ACI5 - ACI6  
 97 primers (Table 1) (10  $\mu$ M), 0.5  $\mu$ l *Taq* DNA polymerase (5.0 UI), 1.0  $\mu$ l bacteria, and distilled  
 98 water. The multiplex PCR program consists of initial denaturation (94 °C, 3 min); 30 cycles of  
 99 denaturation (94 °C/ 1 min), annealing (47 °C /1 min), extension (72 °C /1 min); final extension (72  
 100 °C, 5 min). PCR products were detected by electrophoresis on 1% agarose gel [7,8]. Double  
 101 distilled water was used as a negative control.

102 2.4. *Detection of the ESBL genes of A. baumannii by multiplex PCR technique (E-*  
 103 *PCR)*

104 The E-PCR includes 2.5  $\mu$ l PCR buffer (10X), 1.0  $\mu$ l each of dNTPs (10 mM), 1.0  $\mu$ l each of TEM,  
 105 SHV, CTX-M primers (Table 1) and 0.2  $\mu$ l *Taq* DNA polymerase (5.0 UI), 3.0  $\mu$ l bacteria, and  
 106 distilled water to adjust to a total volume of a 25  $\mu$ l. The multiplex PCR program consists of initial  
 107 denaturation (94 °C, 3 min); 30 cycles of denaturation (94 °C, 30 sec), annealing (55 °C, 1 min),  
 108 extension (72 °C, 1 min); final extension (72 °C, 5 min). PCR products were detected by  
 109 electrophoresis on 1% agarose gel [9–11]. Double distilled water was used as a negative control.

110 **Table 1.** Primer sequences

Primers	Sequence (5' - 3')	Size	Target	Reference
P-Ab-ITSF	CATTATCACGGTAATTAGTG	208 bp	Detect <i>A. baumannii</i>	[5]
P-Ab-ITSB	AGAGCACTGTGCACTTAAG			
P-rA1	CCTGAATCTTCTGGTAAAAC	425 bp	Detect <i>Acinetobacter</i> spp.	[6]
P-rA2	GTTTCTGGGCTGCCAAACATTAC			
OXA-51-like F OXA-51-like R	ATGAACATTAAAGCACTC CTATAAAATACCTAATTGTTC	825 bp	Detect <i>bla</i> <sub>OXA-51-like</sub> gene	[7]
ACI5 ACI6	ACTTACTTCAACTCGCGACG TAAACACCACATATGTTCCG	663 bp	Detect <i>AmpC</i> gene	[8]
TEM-F TEM-R	CATTTCCGTGTCGCCCTTATC CGTTCATCCATAGTTGCCTGAC	800 bp	Detect <i>bla</i> <sub>TEM</sub> gene	[11]
CTX-MF CTX-MR	TCTTCCAGAATAAGGAATCCC CCGTTTCCGCTATTACAAAC	909 bp	Detect <i>bla</i> <sub>CTX-M</sub> gene	[9]
SHV-F SHV-R	AGCCGCTTGAGCAAATTAAC ATCCCGCAGATAAATCACCAC	713 bp	Detect <i>bla</i> <sub>SHV</sub> gene	[11]

111  
 112

## 113 2.5. *In-vitro* antibiotic susceptibility testing

114 *A. baumannii* colonies were dispersed in 0.85% NaCl ~ 0.5 McFarland (1-3 x 10<sup>8</sup> CFU/ml).  
 115 Bacterial suspension of 10<sup>6</sup> CFU/ml would be obtained by a 100 times dilution before being  
 116 spreaded on Mueller Hinton Agar (MHA - Merck) [12]. The antibiotic discs, including imipenem  
 117 (10 µg), cefepime (30 µg), cefotaxime (30 µg), amikacin (30 µg), colistin (10 µg), levofloxacin (5  
 118 µg), and doxycycline (30 µg) were used in disk diffusion method. These plates were incubated at  
 119 37°C for 24 hours in ambient air. Inhibitory zone diameters were measured by the electronic vernier  
 120 caliper (Insize 1112–200). Paper discs were used as a negative control. The inhibitory zone was  
 121 compared to CLSI M100-S28 [13].

## 122 2.6. *Phenotypic detection of ESBL production by combined disc test*

123 Plates were spreaded bacteria on the surface with the process being similar to section 2.5. For  
 124 detecting ESBL producing isolates of *A. baumannii*, combination and alone antibiotic discs (Nam  
 125 Khoa Biotek, Vietnam) were used in the disk diffusion test (Table 2) [14].

126 **Table 2.** Detection of ESBL production by combined disc test


Method	Antibiotic	Testing medium	Interpretation of results	Ref.
CEFOCLA	Using 2 antibiotic discs: cefotaxime (30 µg); cefotaxime/clavulanic acid (30/10 µg).	Muller Hinton Agar (MHA).	A ≥ 5 mm increase in inhibitory zone diameter (IZD) for a combination disc and a single antibiotic disc is regarded as ESBL positive (ESBL(+)), otherwise ESBL negative (ESBL(-)).	[15]
CEFOSUL	Using 2 antibiotic discs: cefotaxime (30 µg); cefotaxime/sulbactam (30/10 µg).	Muller Hinton Agar (MHA).	See above.	[15,16]
CLO-CEFOCLA	Using 2 antibiotic discs: cefotaxime (30 µg); cefotaxime/ clavulanic acid (30/10 µg).	MHA supplementary cloxacillin 200 µg/ml.	See above.	[17]
CEFO-CLA-BO	Using 4 antibiotic discs: cefotaxime (30 µg); cefotaxime/clavulanic acid (30/10 µg); cefotaxime/boronic acid (30/400 µg); cefotaxime/clavulanic acid/boronic acid (30/10/400 µg).	Muller Hinton Agar (MHA).	A ≥ 5 mm increase in IZD for a cefotaxime/clavulanic acid/boronic acid disc versus a cefotaxime disc or a ≥ 3 mm increase in IZD for a cefotaxime/clavulanic acid/boronic acid disc versus a cefotaxime/acid boronic disc indicates ESBL(+), otherwise ESBL(-).	[18,19]

127  
128

### 129 3. Results

#### 130 3.1. Rapid detection of *A. baumannii* by multiplex PCR technique

131 There were 49 isolates of *Acinetobacter* spp. from the clinical samples that were used for multiplex  
132 PCR, and *Bacillus subtilis* PY79 was used as a negative control. The consequence is 46/49 bacterial  
133 isolates from the clinical samples were detected containing the two PCR products ~ 425 bp (*recA*  
134 gene) and ~ 208 bp (ITS 16S - 23S rDNA fragment), which are the specific nucleotide sequences of  
135 *A. baumannii* species. The only *recA* gene (425 bp) exists in the three other samples (5333, 4246,  
136 5378) (Figure 1). This result indicated that 46 isolates are *A. baumannii* and 3 isolates belonged to  
137 the genus *Acinetobacter*. This identification result is the same as that of the biochemical method  
138 with commercial kit IVD NK-IDS 14 GNR (NamKhoa Biotek). Moreover, this experiment used the  
139 colony PCR technique that helps to shorten the time needed for DNA extraction, therefore it  
140 benefits from saving diagnostic costs.




142 **Figure 1.** Multiplex PCR products for detection *A. baumannii*; B: *Bacillus subtilis* strain

#### 143 3.2. Detection of the $\beta$ -lactamase genes of *A. baumannii*

144 There are 45/46 *A. baumannii* isolates possessing two antibiotic resistance genes: *bla*<sub>OXA-51-like</sub> ~ 825  
145 bp (carbapenem resistance gene), *AmpC* ~ 663 bp (cephalosporin resistance gene), while the isolate  
146 5370 expressed merely the *AmpC* gene. Therefore, the *AmpC* gene exists in all 46 isolates of *A.*  
147 *baumannii*; in other words, these isolates would be able to resist the antibiotic cephalosporin group.  
148 *A. baumannii* as well as some other Gram-negative bacteria are capable of producing the *AmpC*  
149 type  $\beta$ -lactamases by expression of *AmpC* gene on chromosome or plasmid. *AmpC* type  $\beta$ -

150 lactamases can deplete penicillin, narrow and broad-spectrum cephalosporin, except carbapenem  
151 and fourth-generation cephalosporins such as cefepime, cefpirome [20]. 45 isolates displayed  
152 *bla*<sub>OXA-51-like</sub> genes that encode for OXA-type carbapenemase [21]. This enzyme is responsible for  
153 hydrolysis of  $\beta$ -lactam antibiotics, especially carbapenem which is one of major antibiotics for  
154 treatment of severe infections caused by *A. baumannii*.




155

156 **Figure 2.** The specific PCR products of some *A. baumannii* isolates and their  $\beta$ -lactamase genes  
157 (a) *recA* gene and ITS fragment; (b) *bla*<sub>OXA-51</sub> gene and *AmpC* gene. Sample 5370 contains only the *AmpC* gene.

### 158 3.3. Detection of the ESBL genes of *A. baumannii*

159 34/46 isolates of *A. baumannii* contain *bla*<sub>TEM</sub> gene (73.9%), however, none of the *bla*<sub>CTX-M</sub> gene or  
160 *bla*<sub>SHV</sub> gene was detected in all 46 isolates. This result seems to be extraordinary compared to other  
161 cases when *bla*<sub>CTX-M</sub> gene is the most common among ESBL genes [10].



162

163 **Figure 3.** The specific PCR products of the *bla*<sub>TEM</sub> gene. NC (-): negative control.

### 164 3.4. In vitro antibiotic susceptibility testing


165 Along with the detection of carbapenem, cephalosporin resistance genes by multiplex PCR, *in vitro*  
166 antibiotic susceptibility testing of 46 isolates of *A. baumannii* by antimicrobial susceptibility testing  
167 was also performed. Six employed antibiotic disc containing antibiotics those are usually used for



168 the treatment of *A. baumannii* are imipenem, cefepime, cefotaxime, amikacin, colistin,  
 169 levofloxacin, doxycycline. The inhibition zone of the 10 randomized representative samples (4145,  
 170 5199, 5308, 5249, 5370, 5247, 4154, 5197 and 5377) are shown in **Table 3** and **Figure 5** (all data  
 171 shown in Supplementary 1).



172 **Figure 4.** Antibiotic susceptibility testing of the three isolates 4145, 5197 and 5377



173

174

**Figure 5.** The rate of antibiotic resistance of 46 *Acinetobacter baumannii* isolates

175 **Table 3.** The inhibition zone of antibiotic susceptibility testing

Isolates	Antibiotic						
	Im (mm) (IZD/REF)	Cm (mm) (IZD/REF)	Ct (mm) (IZD/REF)	Ak (mm) (IZD/REF)	Co (mm)* (IZD/REF)	Lv (mm) (IZD/REF)	Dx (mm) (IZD/REF)
4145	R (9/≤18)	R (12/≤14)	R (7/≤14)	R (7/≤14)	S (12/≥11)	R (7/≤13)	S (15/≥13)
5199	R (8/≤18)	R (8/≤14)	R (7/≤14)	R (7/≤14)	S (11/≥11)	R (7/≤13)	S (15/≥13)
5308	R (8/≤18)	R (8/≤14)	R (7/≤14)	R (7/≤14)	S (11/≥11)	R (7/≤13)	S (14/≥13)
5249	R (8/≤18)	R (8/≤14)	R (7/≤14)	R (14/≤14)	S (11/≥11)	R (7/≤13)	S (16/≥13)
5370	S (28/≥22)	S (22/≥18)	I (18/15-22)	S (23/≥17)	S (11/≥11)	R (12/≤13)	S (13/≥13)
5247	R (8/≤18)	R (12/≤14)	R (7/≤14)	R (7/≤14)	S (12/≥11)	R (7/≤13)	S (16/≥13)

5270	R (10/≤18)	R (10/≤14)	R (7/≤14)	I (15/15-16)	S (14/≥11)	R (7/≤13)	S (19/≥13)
4154	R (8/≤18)	R (11/≤14)	R (7/≤14)	R (7/≤14)	S (11/≥11)	R (7/≤13)	S (14/≥13)
5197	R (9/≤18)	R (10/≤14)	R (7/≤14)	R (7/≤14)	S (11/≥11)	R (7/≤13)	S (15/≥13)
5377	R (7/≤18)	R (9/≤14)	R (7/≤14)	R (7/≤14)	S (12/≥11)	R (7/≤13)	S (15/≥13)

176 IZD: inhibitory zone diameter of antibiotic resistance testing, REF: inhibitory zone diameter of antibiotic sensitivity to *A. baumannii* according to  
177 CLSI. Im: Imipenem, Cm: Cefepime, Ct: Cefotaxime, Ak: Amikacin, Co: Colistin, Lv: Levofloxacin, Do: Doxycycline. R: Resistance; S: Sensitivity;  
178 I: Intermediate resistance. \* In this research, we used colistin discs as a preliminary test, however, updated CLSI's guideline [13] recommends using  
179 MIC value for colistin because of its' poor diffusion. Therefore, we did not discuss this based on the IZD of colistin.  
180

### 181 3.5. Phenotypic detection of ESBL production by combined disc test

182 The method CEFOCLA used cefotaxime alone and combined cefotaxime/clavulanic acid, this test  
183 displayed ESBL(+) on two isolates, 2146 and 1672. Meanwhile, almost all isolates show no  
184 inhibitory zone with combined discs containing cefotaxime/sulbactam, hence, CEFOSUL is not  
185 suitable for identification of ESBL phenotype. We recorded 7 isolates ESBL(+) including 5377,  
186 5197, 5249, 5199, 2146, 1692, 1672 when using MHA containing cloxacillin 200 µg/ml for  
187 combined disc test with cefotaxime and cefotaxime/clavulanic acid. Cloxacillin is known as an  
188 AmpC β-lactamase inhibitor [17].

189 Based on the CEFO-CLA-BO method, we identified 40 out of 46 isolates (87%) expressing  
190 ESBL(+) in which there are 34 isolates possessing *bla<sub>TEM</sub>* and there is not isolate displaying *bla<sub>SHV</sub>*  
191 and *bla<sub>CTX-M</sub>*. The AmpC gene presents in all isolates of this research. This gene encodes for AmpC  
192 β-lactamase which is not inhibited by clavulanic acid or sulbactam. Therefore, the CEFO-CLA-BO  
193 method is effective in applying boronic acid to inactivate the AmpC β-lactamase enzyme [18].

## 194 4. Discussion

195 Only isolate 5370 sensitive to the carbapenem group (imipenem), the remaining 45 out of 46  
196 isolates were resistant to this antibiotic (97.8%). This result is reasonable because no detection of  
197 the *bla<sub>OXA-like-51</sub>* gene in isolate 5370 as shown above. The same as the case of the fourth-generation  
198 cephalosporin (cefepime), only the isolate 5370 is sensitive and the other 45 isolates are resistant  
199 (97.8%), although all 46 isolates contain *AmpC* genes. To be able to discuss this phenomenon, the  
200 *AmpC* gene of the 5370 should be sequenced for comparing with other *AmpC* gene sequences.  
201 Perez F. et al. (2007) showed that although the bacteria have the *AmpC* gene, they resist to  
202 cephalosporins except for cefepime [20]. With the third-generation cephalosporin (cefotaxime) the  
203 resistance and intermediate resistance rate is up to 100%. This is similar to the multiplex PCR

204 results when all of the tested *A. baumannii* have the cephalosporin resistance *AmpC* gene. About the  
205 other antibiotic susceptibility, the aminoglycoside group (amikacin) has a high rate of resistance  
206 and intermediate resistance (97.8%). For the fluoroquinolone group, *A. baumannii* is 100%  
207 resistance to levofloxacin. The cycline group (doxycycline), bacterial sensitivity is about 56.5%, the  
208 rate of resistance and intermediate resistance about 43.5%.

209 This study shows that *A. baumannii* isolated in Binh Duong hospital have been resistant to many  
210 groups of antibiotics with high rates. This result is similar to the reported article which mentioned  
211 antibiotic resistance of *A. baumannii* by the Pasteur Institute in Ho Chi Minh City, Viet Nam [22].  
212 As reported by the Pasteur Institute [22], the percentage of cephalosporin and amikacin resistance  
213 was 96.7%, while in this study, the rate of resistance cephalosporin was 100%, of amikacin was  
214 97.8% (based on antibiotic susceptibility testing). Noticeably, the carbapenem group was used to be  
215 the priority choice antibiotics for infection caused by multidrug resistance *A. baumannii*, but the  
216 high rate of resistance was reported 96.7% and 97.8%, respectively according to the Pasteur  
217 Institute [22] and this study.

218 By multiplex PCR, we identified 46 *A. baumannii* isolated from different clinical departments,  
219 which were resistant to cephalosporins. 45 of 46 samples carry the *bla*<sub>OXA-51-like</sub> gene which is a  
220 specific gene of *A. baumannii*. Among the 46 strains of *A. baumannii* which resist third-generation  
221 cephalosporins, we detected the *AmpC* gene. The *AmpC* gene located on the chromosome or  
222 plasmid and encodes the class C  $\beta$ -lactamase - *AmpC* cephalosporinase enzyme [23].

223 Due to the existence of the *bla*<sub>TEM</sub> gene in the 34 strains of *A. baumannii*, this is evidence of their  
224 ability to produce ESBL. Most data of the ESBL molecular method align with the phenotypic test,  
225 however, 6 isolates (1571, 1672, 1793, 1958, 2146, 5251) expressed ESBL(+) in disc test only.  
226 ESBL(+) associates with different mechanisms, in this research we targeted 3 popular genes  
227 encoded for ESBL including *bla*<sub>SHV</sub>, *bla*<sub>CTX-M</sub>, *bla*<sub>TEM</sub>. This phenomenon could be due to *bla*<sub>SHV</sub> and  
228 *bla*<sub>CTX-M</sub> being not popular in Binh Duong area, while *bla*<sub>TEM</sub> displays in 73.9% isolates of *A.*  
229 *baumannii* in this study.

230 Based on the previous researches, the type of genes responsible for extended-spectrum  $\beta$ -lactamases  
231 is different in local areas. According to a report in Saudi Arabia in 2015 [10], there were 71%  
232 *bla*<sub>TEM</sub> gene, none of *bla*<sub>SHV</sub> gene and 81% *bla*<sub>CTX-M</sub> gene. While research of Safari M et al. (2015)  
233 in Hamadan City in Iran [9] showed that there were *bla*<sub>CTX-M</sub> 20%, *bla*<sub>SHV</sub> 58% and *bla*<sub>TEM</sub> 0% from  
234 the isolated *A. baumannii*. However, following the research on *A. baumannii* from Tehran hospitals  
235 of Melika Sharif *et al*, these rates were *bla*<sub>SHV</sub> 63% and *bla*<sub>TEM</sub> 56% [11].

## 236 **5. Conclusions**

237 Acquired hospital infection caused by the Gram (-) bacteria of the genus *Acinetobacter* is a serious  
238 problem due to increasing the severity of the disease, lengthening treatment duration, increasing  
239 treatment costs and increasing mortality. Thus, the rapid and accurate identification of *A. baumannii*  
240 as well as their resistance antibiotic genes plays an important role. Applying the molecular method  
241 can overcome these above difficulties. Particularly, the colony PCR technique helps not only to  
242 shorten the consumption of time needed for bacterial culture and the extraction of chromosomal  
243 DNA but also to save on diagnostic costs. Furthermore, based on the rapid result of multiplex PCR  
244 done directly from colony, clinicians can prescribe effective antibiotics, resulting in reduction of the  
245 incidence of this disease as well as patients will also progress better. Meanwhile, identification of  
246 bacteria or of their antibiotic susceptibility by traditional microbiology methods such as  
247 biochemical tests and antimicrobial susceptibility tests take a lot of time, effort and in some cases it  
248 is difficult to explain unclear identification results.

249 Two multiplex PCR detection procedures were set up including detection of the specific genes of  
250 the strain *A. baumannii* based on the *recA* gene and the ITS 16S - 23S rDNA fragment,  $\beta$ -lactamase  
251 producers based on the two genes *bla*<sub>OXA-51</sub> gene coding carbapenemase and the *AmpC* gene coding  
252 cephalosporinase. In addition, one simple PCR test were designed for detecting *bla*<sub>TEM</sub> gene. The  
253 results of this tests are the same as those of the *in vitro* antibiotic sensitivity testing of *A. baumannii*  
254 using the antimicrobial susceptibility technique except for the case of screening ESBL using the  
255 combination disc method.

## 256 6. Acknowledgements

257 We would like to thank General Hospital Binh Duong for providing the *A. baumannii* from the  
258 clinical isolates.

259 **Funding:** This work was supported by University of Medicine and Pharmacy at Ho Chi Minh City  
260 [grant numbers 139-17, 2017].

261 Ethical Approval  
262

## 263 7. References

- 264 [1] World Health Organization. Report on the burden of endemic health care-associated infection  
265 worldwide 2011.
- 266 [2] Eliopoulos GM, Maragakis LL, Perl TM. *Acinetobacter baumannii*: epidemiology, antimicrobial  
267 resistance, and treatment options. *Clinical Infectious Diseases* 2008;46:1254–63.
- 268 [3] Centres for Disease Control and Prevention (US). Antibiotic resistance threats in the United States,  
269 2013. Centres for Disease Control and Prevention,; 2013.
- 270 [4] GARP – Vietnam National Working Group. Situation analysis: antibiotic use and resistance in  
271 Vietnam. Vietnam: 2010.
- 272 [5] Chang HC, Wei YF, Dijkshoorn L, Vaneechoutte M, Tang CT, Chang TC. Species-level identification  
273 of isolates of the *Acinetobacter calcoaceticus* -*Acinetobacter baumannii* complex by sequence analysis  
274 of the 16S-23S rRNA gene spacer region. *Journal of Clinical Microbiology* 2005;43:1632–9.  
275 <https://doi.org/10.1128/JCM.43.4.1632-1639.2005>.
- 276 [6] Chiang M-C, Kuo S-C, Chen Y-C, Lee Y-T, Chen T-L, Fung C-P. Polymerase chain reaction assay for  
277 the detection of *Acinetobacter baumannii* in endotracheal aspirates from patients in the intensive care  
278 unit. *Journal of Microbiology, Immunology and Infection* 2011;44:106–10.  
279 <https://doi.org/doi.org/10.1016/j.jmii.2010.04.003>.
- 280 [7] Coelho J, Woodford N, Afzal-Shah M, Livermore D. Occurrence of OXA-58-like carbapenemases in  
281 *Acinetobacter* spp. collected over 10 years in three continents. *Antimicrobial Agents and*  
282 *Chemotherapy* 2006;50:756–8. <https://doi.org/10.1128/AAC.50.2.756-758.2006>.
- 283 [8] Corvec S, Caroff N, Espaze E, Giraudeau C, Drugeon H, Reynaud A. AmpC cephalosporinase  
284 hyperproduction in *Acinetobacter baumannii* clinical strains. *Journal of Antimicrobial Chemotherapy*  
285 2003;52:629–35. <https://doi.org/10.1093/jac/dkg407>.
- 286 [9] Safari M, Nejad ASM, Bahador A, Jafari R, Alikhani MY. Prevalence of ESBL and MBL encoding  
287 genes in *Acinetobacter baumannii* strains isolated from patients of intensive care units (ICU). *Saudi*  
288 *Journal of Biological Sciences* 2015;22:424–9. <https://doi.org/10.1016/j.sjbs.2015.01.004>.
- 289 [10] Alyamani EJ, Khiyami MA, Booq RY, Alnafjan BM, Altammami MA, Bahwerth FS. Molecular  
290 characterization of extended-spectrum beta-lactamases (ESBLs) produced by clinical isolates of  
291 *Acinetobacter baumannii* in Saudi Arabia. *Annals of Clinical Microbiology and Antimicrobials*  
292 2015;14:38. <https://doi.org/10.1186/s12941-015-0098-9>.
- 293 [11] Sharif M, Mirnejad R, Amirmozafari N. Molecular identification of TEM and SHV extended spectrum  
294  $\beta$ -lactamase in clinical isolates of *Acinetobacter baumannii* from Tehran hospitals. *J Gen Microb*  
295 *Immun* 2014;2:1–9. <https://doi.org/10.5899/2014/jgmi-00020>.
- 296 [12] Leber AL. *Clinical microbiology procedures handbook*. vol. 2. John Wiley & Sons; 2016.

- 297 [13] Patel J, Weinstein M, Eliopoulos G, Jenkins S, Lewis J, Limbago B. M100 Performance standards for  
298 antimicrobial susceptibility testing. United State: Clinical and Laboratory Standards Institute 2018;240.
- 299 [14] Drieux L, Brossier F, Sougakoff W, Jarlier V. Phenotypic detection of extended-spectrum  $\beta$ -lactamase  
300 production in Enterobacteriaceae: review and bench guide. *Clinical Microbiology and Infection*  
301 2008;14:90–103. <https://doi.org/10.1111/j.1469-0691.2007.01846.x>.
- 302 [15] European Committee on Antimicrobial Susceptibility Testing. EUCAST guidelines for detection of  
303 resistance mechanisms and specific resistances of clinical and/or epidemiological importance (Version  
304 2). EUCAST, Basel, Switzerland 2017:43.
- 305 [16] Akova M. Sulbactam-containing  $\beta$ -lactamase inhibitor combinations. *Clinical Microbiology and*  
306 *Infection* 2008;14:185–8. <https://doi.org/10.1111/j.1469-0691.2007.01847.x>.
- 307 [17] Al Naiemi N, Murk JL, Savelkoul PHM, Vandenbroucke-Grauls CMJ, Debets-Ossenkopp YJ.  
308 Extended-spectrum beta-lactamases screening agar with AmpC inhibition. *European Journal of*  
309 *Clinical Microbiology & Infectious Diseases* 2009;28:989–90. [https://doi.org/10.1007/s10096-009-](https://doi.org/10.1007/s10096-009-0714-8)  
310 0714-8.
- 311 [18] Tsakris A, Poulou A, Themeli-Digalaki K, Voulgari E, Pittaras T, Sofianou D, et al. Use of Boronic  
312 Acid Disk Tests To Detect Extended- Spectrum  $\beta$ -Lactamases in Clinical Isolates of KPC  
313 Carbapenemase-Possessing Enterobacteriaceae. *J Clin Microbiol* 2009;47:3420.  
314 <https://doi.org/10.1128/JCM.01314-09>.
- 315 [19] Song W, Bae IK, Lee Y-N, Lee C-H, Lee SH, Jeong SH. Detection of Extended-Spectrum  $\beta$ -  
316 Lactamases by Using Boronic Acid as an AmpC  $\beta$ -Lactamase Inhibitor in Clinical Isolates of  
317 *Klebsiella* spp. and *Escherichia coli*. *J Clin Microbiol* 2007;45:1180.  
318 <https://doi.org/10.1128/JCM.02322-06>.
- 319 [20] Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-  
320 resistant *Acinetobacter baumannii*. *Antimicrobial Agents and Chemotherapy* 2007;51:3471–84.  
321 <https://doi.org/10.1128/AAC.01464-06>.
- 322 [21] Brown S, Young HK, Amyes SGB. Characterisation of OXA-51, a novel class D carbapenemase found  
323 in genetically unrelated clinical strains of *Acinetobacter baumannii* from Argentina. *Clinical*  
324 *Microbiology and Infection* 2005;11:15–23. <https://doi.org/10.1111/j.1469-0691.2004.01016.x>.
- 325 [22] Pham Hung Van, the MIDAS. The multicenter study on the resistance to imipenem and meropenem of  
326 the the non-fastidious gram (-) rods – the results from 16 hospitals in Việt Nam (Nghiên cứu đa trung  
327 tâm về tình hình đề kháng imipenem và meropenem của trực khuẩn gram (-) dễ mọc - kết quả trên 16  
328 bệnh viện tại Việt Nam). *Ho Chi Minh City Journal of Medicine* 2010;14:280–6.
- 329 [23] Thomson KS. Extended-spectrum- $\beta$ -lactamase, AmpC, and carbapenemase issues. *Journal of Clinical*  
330 *Microbiology* 2010;48:1019–25. <https://doi.org/10.1128/JCM.00219-10>.
- 331